USA F.D.A Approves "Lenacapavir" With 99.9% Reduction Risk of HIV Infections

On June 19, 2025, the US FDA granted approval to Gilead Sciences’ lenacapavir, a twice-yearly injection designed to prevent HIV infection in adults and adolescents. This groundbreaking development marks a significant milestone in the fight against HIV, offering a promising new option for individuals at high risk of contracting the virus.

 Lenacapavir, marketed under the brand name Yeztugo, has demonstrated remarkable efficacy in clinical trials, with a staggering 99.9% reduction in HIV infections among participants.

Lenacapavir’s approval brings hope to millions of people worldwide, particularly those in low- and lower-middle-income countries. Gilead Sciences is committed to making this life-changing medication accessible to those in need, partnering with generic manufacturers to ensure its availability in regions where it is most required. 

The list price for lenacapavir in the US is $42,250 for the first year, with a reduced price of $28,218 per year thereafter. However, UNAIDS has urged Gilead to reconsider the pricing, citing research suggesting that lenacapavir could be produced for as little as $35-$46 per person-year, making it an affordable option for those in need.

The approval of lenacapavir is not just a victory for the scientific community but also a testament to the unwavering dedication of healthcare professionals and researchers. This narrative serves as a reminder that, with determination and collaboration, we can overcome even the most daunting challenges and pave the way for a brighter, healthier future for all.